Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension

Table 4 Changes in prophylactic treatment (drug and daily dose) between baseline and the end of the open phase

Patient	Long-term responder	Before implantation	1-year follow-up
C1P1	Yes	Verapamil 240 mg	No treatment
C1P1	Yes	Lithium 800 mg	No treatment
C1P2	No	Verapamil 1440 mg	Verapamil 1440 mg
C1P3	No	Verapamil 1200 mg	Verapamil 1200 mg
C1P4	Yes	Verapamil 600 mg	Verapamil 1080 mg
C1P4	Yes	Lithium 400 mg	Verapamil 1080 mg
C1P5	No	Verapamil 720 mg	No treatment
C1P5	No	Lithium 800 mg	No treatment
C2P1	Yes	Verapamil 960 mg	Verapamil 360 mg
C2P1	Yes	Lithium 1000 mg	Lithium 500 mg
C2P2	Yes	Lithium 800 mg	Divalproex 1500 mg
C2P2	Yes	Lithium 800 mg	Fluoxetine 40 mg
C3P1	Yes	Verapamil 360 mg	Verapamil 360 mg
C3P1	Yes	Prednisone 20 mg	Verapamil 360 mg
C3P2	No	Verapamil 480 mg	Verapamil 480 mg
C4P1	Yes	Verapamil 720 mg	Verapamil 720 mg
C4P2	No	No	Verapamil 240 mg

Long-term responders were defined as patients with weekly attack frequency decrease ≥50% at the end of the open phase, compared to baseline

ISSN: 1129-2377